Evidence map›Paper›PMID 24482750›Full record

ArticleOncoimmunology2013

Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

Andrea Schietinger, Ainhoa Arina, Rebecca B Liu, Sam Wells, Jianhua Huang, Boris Engels, Vytas Bindokas, Todd Bartkowiak, David Lee, Andreas Herrmann and 5 more

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. CD4Science immunology · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Modulation of T cell function and survival by the tumor microenvironment.Frontiers in cell and developmental biology · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Reduced CTL motility and activity in avascular tumor areas.Cancer immunology, immunotherapy : CII · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Frontiers in immunology · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Andrea SchietingerDepartment of Pathology; The University of Chicago; Chicago, IL USA.
Ainhoa ArinaDepartment of Pathology; The University of Chicago; Chicago, IL USA.
Rebecca B LiuDepartment of Pathology; The University of Chicago; Chicago, IL USA.
Sam WellsDepartment of Physiology and Biophysics; Vanderbilt University School of Medicine; Nashville, TN USA.
Jianhua HuangDepartment of Radiation Oncology and The Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine; Nashville, TN USA.
Boris EngelsDepartment of Pathology; The University of Chicago; Chicago, IL USA.
Vytas BindokasIntegrated Microscopy Core; The University of Chicago; Chicago, IL USA.
Todd BartkowiakDepartment of Immunology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
David LeeSchool of Medicine; The University of Chicago; Chicago, IL USA.
Andreas HerrmannDepartments of Cancer Immunotherapeutics & Tumor Immunology; City of Hope; Duarte, CA USA.
David W PistonDepartment of Physiology and Biophysics; Vanderbilt University School of Medicine; Nashville, TN USA.
Mikael J PittetCenter for Systems Biology; Massachusetts General Hospital and Harvard Medical School; Boston, MA USA.
P Charles LinDepartment of Radiation Oncology and The Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine; Nashville, TN USA ; Center for Cancer Research; National Cancer Institute, NIH; Frederick, MD USA.
Tomasz ZalDepartment of Immunology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
Hans SchreiberDepartment of Pathology; The University of Chicago; Chicago, IL USA.
University of Chicago · USVanderbilt University · USThe University of Texas MD Anderson Cancer Center · USCity Of Hope National Medical Center · USHarvard University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Protein Expression and Peptide CoreP01CA097296 · NCI · UNIVERSITY OF CHICAGO · PI SCHREIBER, HANS · 2003 to 2012
$15.0M
PATHOBIOLOGY OF MYELOMA AND ANTI-IDIOTYPIC IMMUNITYR01CA022677 · NCI · UNIVERSITY OF CHICAGO · PI SCHREIBER, HANS · 1985 to 2024
$6.3M
Novel Molecular Targets of Neoplasia in the EsophagusU54CA105296 · NCI · STANFORD UNIVERSITY · PI CONTAG, CHRISTOPHER H · 2004 to 2008
$5.7M
IMMUNOLOGY OF UNIQUE TUMOR-SPECIFIC ANTIGENSR01CA037156 · NCI · UNIVERSITY OF CHICAGO · PI SCHREIBER, HANS · 1985 to 2017
$3.1M
Probes:Quantitative Optical and Electron Microscopy(RMI)P20GM072048 · NIGMS · VANDERBILT UNIVERSITY · PI PISTON, DAVID W. · 2004 to 2007
$2.7M
Immune cell interactions during tumor establishment.R01CA137059 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2009 to 2013
$1.6M
VANDERBILT IN VIVO IMAGING CENTERP20CA086283 · NCI · VANDERBILT UNIVERSITY · PI PISTON, DAVID W. · 2000 to 2002
$1.2M
Multi-Function Laser Scanning MicroscopeS10RR025649 · NCRR · VANDERBILT UNIVERSITY · PI PISTON, DAVID W · 2009 to 2009
$499k
Multiphoton microscope upgradeS10OD010681 · OD · VANDERBILT UNIVERSITY · PI PISTON, DAVID W · 2012 to 2012
$436k
NCI NIH HHS P01 CA097296NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA022677NCI NIH HHS R01 CA037156NCI NIH HHS R01 CA137059NCI NIH HHS U54 CA105296NCRR NIH HHS S10 RR025649NIGMS NIH HHS P20 GM072048NIH HHS S10 OD010681
6 · The paper itself

Abstract

A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid tumors that had developed behind windows implanted on the backs of mice. Events could be followed repeatedly within precisely the same tumor region-before, during and after adoptive T cell therapy-thereby enabling for the first time a longitudinal in vivo evaluation of protracted events, an analysis not possible with terminal imaging of surgically exposed tumors. T cell infiltration, stromal interactions, and vessel destruction, as well as the functional consequences thereof, including the elimination of cancer cells and cancer cell variants were studied. Minimal perivascular T cell infiltrates initiated vascular destruction inside the tumor mass eventually leading to macroscopic central tumor necrosis. Prolonged engagement of T cells with tumor antigen-crosspresenting stromal cells correlated with high IFNγ cytokine release and bystander elimination of antigen-negative cancer cells. The high-resolution, longitudinal, in vivo imaging approach described here will help to further a better mechanistic understanding of tumor eradication by T cells and other anti-cancer therapies.

Indexed as

cancerCD8 T cellimagingstromatumor immunologytumor microenvironment

Identifiers

PMID24482750
PMCPMC3895414
OpenAlexW2130627595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.